Invion Ltd
IVX
Company Profile
Business description
Invion Ltd is an Australian clinical-stage pharmaceutical drug development company. It is engaged in the development of PhotoDynamic Therapy (PDT) for cancer treatments. The company produces topical and intravenous products suitable for use in skin cancer and solid tumors, such as ovarian, prostate, and lung cancer.
Contact
692 High Street
East KewVIC3102
AUSSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2025
Employees
4
Stocks News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
What next for Tesla as 2024 deliveries disappoint?
Tesla shares started the year on a sour note. We think they continue to price in ambitious growth going forward.
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,611.00 | 68.10 | 0.80% |
| CAC 40 | 7,489.35 | 43.66 | 0.59% |
| DAX 40 | 20,340.57 | 124.38 | 0.62% |
| Dow JONES (US) | 42,528.36 | 178.20 | -0.42% |
| FTSE 100 | 8,245.28 | 4.38 | -0.05% |
| HKSE | 19,137.88 | 309.70 | -1.59% |
| NASDAQ | 19,489.68 | 375.30 | -1.89% |
| Nikkei 225 | 40,074.25 | 9.05 | -0.02% |
| NZX 50 Index | 13,043.11 | 1.05 | 0.01% |
| S&P 500 | 5,909.03 | 66.35 | -1.11% |
| S&P/ASX 200 | 8,362.90 | 77.80 | 0.94% |
| SSE Composite Index | 3,182.48 | 47.17 | -1.46% |